Is tirzepatide just a stronger semaglutide?

No. They are different molecules with different targets — semaglutide engages the GLP-1 receptor, tirzepatide engages both GIP and GLP-1. Describing one as a stronger version of the other misstates what the difference is.

Can I switch from one to the other?

That is a prescriber decision. Switching between these medicines involves both a clinical judgement and a practical one about coverage and supply, and it is not something to arrange yourself.

Which one is cheaper?

There is no stable answer. What you pay depends on the brand, the licensed indication, your plan's formulary, and which savings or cash-pay routes you qualify for. Two people prescribed the same drug on the same day routinely pay very different amounts.

Do both need a prescription?

Yes. Both molecules are prescription-only in the United States under every brand they are sold as.

Is one available as a tablet?

Semaglutide has an oral form licensed for type 2 diabetes. Tirzepatide is injection-only.

Semaglutide vs tirzepatide

The mechanical difference is easy to state. Semaglutide acts on one receptor, GLP-1. Tirzepatide acts on two, GIP and GLP-1. Everything else — how you take it, what it is licensed for, what it costs you — follows from which brand and which indication your prescriber is working from, not from the molecule name on its own.

This page lays out what separates them and what does not. It does not rank them, because the honest answer to "which is better" is that it depends on your medical history, what your insurer covers, and which one your prescriber can actually get for you.

SemaglutideGLP-1 receptor agonist
TirzepatideGIP + GLP-1 receptor agonist
BothPrescription only
RouteWeekly injection

What each molecule does

Semaglutide is a GLP-1 receptor agonist. GLP-1 is an incretin hormone your gut releases after you eat, and semaglutide is built to mimic it while lasting far longer in the body than the natural hormone does.

Tirzepatide is a dual agonist. It engages the GLP-1 receptor as well, but it also engages the GIP receptor — a second incretin pathway. That second target is the entire structural difference between the two drugs, and it is why tirzepatide is sometimes described as a newer class rather than a newer version.

What research explores is whether engaging both pathways changes outcomes relative to engaging one. That is an active question in the literature, and it is a question for your prescriber to interpret against your history — not something a comparison page should settle for you.

The brand names, and why they matter more than the molecule

Both molecules are sold under more than one brand, and the brands are licensed for different things. This trips people up constantly, because two products can contain the same active ingredient and still be prescribed for different reasons.

Molecule / Brand / Licensed for / How it is taken
Molecule	Brand	Licensed for	How it is taken
Semaglutide	Ozempic	Type 2 diabetes	Weekly injection
Semaglutide	Wegovy	Chronic weight management	Weekly injection
Semaglutide	Rybelsus	Type 2 diabetes	Daily tablet
Tirzepatide	Mounjaro	Type 2 diabetes	Weekly injection
Tirzepatide	Zepbound	Chronic weight management	Weekly injection

Semaglutide has an oral form; tirzepatide does not. If swallowing a daily tablet rather than using a weekly injector matters to you, that is currently a real point of difference, and it only exists on the semaglutide side.

What drives what you pay

We do not publish a price on this page, because any number we printed would be wrong for most readers and stale within months. What we can do is tell you which levers actually move the figure, so you know what to ask.

Which brand you are prescribed. The diabetes-labeled and weight-labeled versions of the same molecule are priced and covered separately.
Whether your plan covers the indication. Many plans cover a diabetes indication and exclude weight management outright, which is the single biggest swing factor.
Manufacturer savings programs, which are usually conditional on having commercial insurance and are not open to everyone.
Cash-pay and direct-from-manufacturer pharmacy routes, which exist for some presentations and not others.
Whether you are being offered a compounded version rather than the branded product — see the section below, because this is not simply a cheaper equivalent.

Ask any prescriber or program for the total monthly cost to you, in writing, including what happens when a savings program or introductory rate ends. That one question separates a real quote from a headline number.

About compounded versions

During the shortages, compounding pharmacies were permitted to prepare copies of these drugs under specific federal allowances tied to a drug being in shortage. The FDA subsequently declared both the tirzepatide and the semaglutide shortages resolved, which narrowed that permission substantially.

The practical consequence: a compounded version is not simply a generic. It has not been through the approval process the branded product went through, and the rules governing who may prepare one have tightened. If a program offers you a compounded version, ask which pharmacy prepares it, under what authority, and what testing the finished preparation goes through.

How to decide

Bring three things to the appointment: your full medication list, your insurance card, and a clear statement of what you are trying to achieve. The prescriber's job is to weigh your history — including anything in your family history that would rule either drug out — against what is actually available to you.

Dosing is determined by a licensed provider. Any source handing you a schedule of numbers before anyone has looked at your history is not doing you a favour.

How we verify providers

Questions

Semaglutide vs tirzepatide: common questions

Is tirzepatide just a stronger semaglutide?: No. They are different molecules with different targets — semaglutide engages the GLP-1 receptor, tirzepatide engages both GIP and GLP-1. Describing one as a stronger version of the other misstates what the difference is.
Can I switch from one to the other?: That is a prescriber decision. Switching between these medicines involves both a clinical judgement and a practical one about coverage and supply, and it is not something to arrange yourself.
Which one is cheaper?: There is no stable answer. What you pay depends on the brand, the licensed indication, your plan's formulary, and which savings or cash-pay routes you qualify for. Two people prescribed the same drug on the same day routinely pay very different amounts.
Do both need a prescription?: Yes. Both molecules are prescription-only in the United States under every brand they are sold as.
Is one available as a tablet?: Semaglutide has an oral form licensed for type 2 diabetes. Tirzepatide is injection-only.

Talk to a licensed prescriber about which one fits you

We do not prescribe, and we do not pick for you. We point you at licensed providers who can assess your situation, check your coverage, and tell you what each option would actually mean for you.

Find a licensed prescriber

TreatRadar is an information and referral service. We are not a medical provider, we do not practise medicine, and nothing here is medical advice, diagnosis, or a treatment recommendation. Decisions about treatment belong to you and a licensed clinician who knows your history.

We may be compensated when you connect with a provider through this site. That never changes which providers we list or how we describe them — how we verify providers.

Some information (pricing, provider coverage, state rules) may change or await verification — confirm details directly with the provider or the relevant state medical board before booking.